Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives $7.30 Average Price Target from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned an average rating of “Hold” from the five brokerages that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $7.30.

A number of equities research analysts recently commented on ESPR shares. Cantor Fitzgerald initiated coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They set an “overweight” rating and a $8.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Esperion Therapeutics in a research note on Friday, December 13th. The Goldman Sachs Group began coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 price objective on the stock. StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th.

Esperion Therapeutics Price Performance

Shares of ESPR stock opened at $2.21 on Friday. The business has a fifty day moving average of $2.47 and a 200 day moving average of $2.18. The firm has a market capitalization of $435.46 million, a price-to-earnings ratio of -3.45, a price-to-earnings-growth ratio of 0.17 and a beta of 1.03. Esperion Therapeutics has a 1 year low of $1.58 and a 1 year high of $3.94.

Institutional Trading of Esperion Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Boomfish Wealth Group LLC raised its position in shares of Esperion Therapeutics by 17.1% in the third quarter. Boomfish Wealth Group LLC now owns 34,997 shares of the biopharmaceutical company’s stock worth $58,000 after acquiring an additional 5,102 shares during the period. National Bank of Canada FI raised its holdings in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock worth $44,000 after purchasing an additional 10,225 shares during the period. BOKF NA purchased a new position in Esperion Therapeutics during the second quarter worth approximately $26,000. Xponance Inc. acquired a new stake in Esperion Therapeutics in the second quarter valued at approximately $28,000. Finally, Traphagen Investment Advisors LLC purchased a new stake in shares of Esperion Therapeutics in the third quarter valued at approximately $27,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.